My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Janux Therapeutics, Inc. - Common Stock (NQ:JANX)

13.14 +0.01 (+0.08%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Janux Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >

Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

August 08, 2023

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

July 17, 2023

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

July 17, 2023

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development

June 05, 2023

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 09, 2023

From Janux Therapeutics

Via Business Wire

Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences

April 24, 2023

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors

April 20, 2023

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

March 10, 2023

From Janux Therapeutics

Via Business Wire

Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference

February 14, 2023

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors

December 27, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics to Present at Upcoming Investor Conferences in November

November 22, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

November 10, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer

October 12, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources

September 23, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics Appoints Winston Kung to Board of Directors

September 22, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September

August 31, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

August 09, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference

June 02, 2022

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer

May 31, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

May 10, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr

April 26, 2022

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

March 18, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference

January 05, 2022

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results

November 09, 2021

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics to Present Virtually at Upcoming Investor Conferences

November 08, 2021

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors

September 09, 2021

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference

September 07, 2021

From Janux Therapeutics, Inc.

Via Business Wire

Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer

July 19, 2021

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

June 15, 2021

From Janux Therapeutics, Inc.

Via Business Wire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.